Novartis's pain drug among latest MHRA reclassifications
This article was originally published in Scrip
Novartis's 12.5mg immediate-release tablets of diclofenac potassium, Voltarol Pain-Eze, are now available without a prescription after the UK medicines regulator, theMHRA, reclassified them to over-the-counter pharmacy status. Novartis proposed the change in November 2007 (Scrip No 3315, p 3) when it said that the product was already marketed in more than 50 countries as an OTC drug. In its round-up of reclassifications over the past 12 months, the MHRA reports that it has reclassified naproxen 250mg tablets from prescription-only to pharmacy status. It has also moved diclofenac diethylammonium from pharmacy-only status to the general sales list (GSL), and increased its maximum pack size from 30g to 50g. Cetirizine is also now available on general sale and its maximum pack size has been increased from seven to 14 tablets. The MHRA says that the Commission on Human Medicines has advised against the reclassification of fluconazole 150mg capsules from pharmacy to GSL status, following concerns raised during the public consultation exercise.
You may also be interested in...
Cerimon Pharmaceuticals' once-daily topical-patch formulation of the NSAID diclofenac gave significantly better average pain relief than placebo in ankle-sprain patients who carried out their daily activities in a Phase II trial, at the third day in the study.
Following a second resubmission, the Scottish Medicines Consortiumhas accepted Lilly's Alimta (pemetrexed) for restricted use within the Scottish NHS as a monotherapy for the second-line treatment of locally advanced or metastatic non-small cell lung cancer.